Hyloris Raises €80m For Business Development

Company Anticipates First European Approval

With the main aim of developing its existing product portfolio and pursuing business development opportunities in the US, Hyloris Pharmaceuticals has successfully raised €80m through a public listing. The company has announced its financial results for the first half of 2020.

Speech_Bubble_Funding
After launching its initial public offering, the Belgian value-added medicine specialist successfully raises €80m through public listing. • Source: Shutterstock

Hyloris Pharmaceuticals SA, a value-added medicines specialist, has successfully raised €80m ($94.6m) through a public listing for the “development of the existing product portfolio, the establishment of infrastructure in the US for the commercialization of the IV cardiovascular portfolio and further expansion of the pipeline, both internally and through business development opportunities.”

Stijn Van Rompay, CEO of Hyloris, commented: “Having successfully completed our public listing on Euronext Brussels, we are well positioned...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business